Please Note: This trial is no longer enrolling new participants
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naive Patients with Mayo Stage IIIa AL Amyloidosis
| Protocol No. | CTO-CAEL101-302 | Scope | National |
|---|---|---|---|
| Principal Investigator | Rafat Abonour | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
